We came across a bullish thesis on Ocular Therapeutix, Inc. on r/Valueinvesting by Senior-Preference678. In this article, we will summarize the bulls’ thesis on OCUL. Ocular Therapeutix, Inc.’s share was trading at $8.88 as of February 16th.
l i g h t p o e t/Shutterstock.com
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. OCUL has emerged at the center of renewed acquisition speculation as rumors suggest that Sanofi may be preparing a significantly higher bid of around $30 per share, up from the $16 offer rejected last year when OCUL traded near $10.50.
The urgency for Sanofi is clear: Dupixent, its blockbuster biologic, faces loss of exclusivity in 2031, and with expected 2025 revenues of approximately $18 billion, the company is seeking a new growth driver. Ocular’s pipeline, particularly its wet AMD and diabetic eye disease programs, offers Sanofi exposure to a $15 billion-plus neovascular market. Recent regulatory developments, including potential FDA approval based on a single Phase 3 trial, could accelerate commercialization and make OCUL a strategically valuable asset.
Investors are now positioning for a range of outcomes: in a bullish scenario, strong trial results could compel Sanofi to pay $25 or more per share, reflecting the company’s long-term potential and validating its confidence in SOL-1. Even in a base-case scenario where the deal is completed in the $18–$22 range, shareholders would capture significant upside from current levels.
While the stock has experienced classic biotech volatility in response to speculation, OCUL’s fundamentals and high-value pipeline suggest that the company remains well-positioned to deliver meaningful returns, whether through a strategic acquisition or continued development of its innovative ophthalmic therapies. The upcoming top-line results on February 17 are poised to be a pivotal catalyst, potentially unlocking substantial value for investors and reinforcing the company’s role as a next-generation growth story in ophthalmology.
Previously, we covered a bullish thesis on AbbVie Inc. (ABBV) by Magnus Ofstad in May 2025, which highlighted the company’s strong Q1 performance, robust momentum in immunology, oncology breakthroughs with Elahere, and strategic acquisitions supporting long-term growth. ABBV’s stock price has appreciated by approximately 16.64% since our coverage. Senior-Preference678 shares a bullish view on Ocular Therapeutix, Inc. (OCUL) but emphasizes potential Sanofi acquisition and its retinal disease pipeline, with upcoming trial results poised to unlock significant investor upside.
Ocular Therapeutix, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 44 hedge fund portfolios held OCUL at the end of the third quarter which was 27 in the previous quarter. While we acknowledge the risk and potential of OCUL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than OCUL and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW
Disclosure: None.
